- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eisai Co., Ltd. (4523)
Eisai Co., Ltd. stock price live, this page displays TYO 4523 stock exchange data. View the 4523 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Eisai Co., Ltd. real time stock price chart below.
What Is the Eisai Co., Ltd. Stock Price Today?
The Eisai Co., Ltd. stock price today is 4,872.0.
What Is the Stock Symbol for Eisai Co., Ltd.?
The stock symbol for Eisai Co., Ltd. is "4523."
What Stock Exchange Does Eisai Co., Ltd. Trade On?
Eisai Co., Ltd. is listed and trades on the Tokyo stock exchange.
Is Eisai Co., Ltd. a Good Stock to Buy?
Determining whether Eisai Co., Ltd.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4523 quote. (ISIN: JP3160400002)
What Is the Eisai Co., Ltd. Stock Price Today?
The Eisai Co., Ltd. stock price today is 4,872.0.
What Is the Stock Symbol for Eisai Co., Ltd.?
The stock symbol for Eisai Co., Ltd. is "4523."
What Stock Exchange Does Eisai Co., Ltd. Trade On?
Eisai Co., Ltd. is listed and trades on the Tokyo stock exchange.
Is Eisai Co., Ltd. a Good Stock to Buy?
Determining whether Eisai Co., Ltd.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4523 quote. (ISIN: JP3160400002)
Currency in JPY
4,872.0
0.0(0.00%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4,852.0
4,902.0
52 wk Range
3,660.0
5,349.0
4523 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4,852.04,902.0
52 wk Range
3,660.05,349.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.21%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.21%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
4523 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
4,496.4
Downside
-7.71%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Pharmaceuticals industry
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
4 Buy
9 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4,496.4
(-7.71% Downside)
Eisai Co., Ltd. Earnings Call Summary for Q1/2027
- Eisai Q1 revenue rose 15.6% to JPY 234.3B, beating forecast by 9.5%; operating profit up 19.2% to JPY 24.7B, net profit climbed 26% to JPY 18.2B.
- Growth driven by LENVIMA, DAYVIGO, and LEQEMBI; company reached first-ever commercial profitability excluding LEQEMBI R&D spending.
- Stock fell 3.56% to $4,656 despite beat, as investors weigh heavy R&D and SG&A spending against future growth potential and LEQEMBI adoption risks.
- Full-year guidance maintained: LENVIMA JPY 345B, DAYVIGO JPY 73.5B, LEQEMBI JPY 143.5B; subcutaneous LEQEMBI IQLIK launch expected late August 2027.
- Management highlights LEQEMBI as only long-term anti-amyloid therapy; focuses on Medicare Part D listing in 2027 and expanding Alzheimer's treatment infrastructure.
Last Updated: 2026-08-03, 05:06 a/m
Read Full TranscriptEarnings
Latest Release
Aug 03, 2026
EPS / Forecast
64.71 / 55.37
Revenue / Forecast
234.33B / 214.01B
Compare 4523 to Peers and Sector
Metrics to compare | 4523 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4523PeersSector | |
|---|---|---|---|---|
P/E Ratio | 32.5x | 20.7x | −0.4x | |
PEG Ratio | −2.06 | 0.19 | 0.00 | |
Price/Book | 1.5x | 1.7x | 2.6x | |
Price / LTM Sales | 1.6x | 2.3x | 3.1x | |
Upside (Analyst Target) | −7.7% | 16.6% | 48.4% | |
Fair Value Upside | Unlock | 14.2% | 6.5% | Unlock |
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Eisai (4523) Stock Price Today?
The Eisai stock price today is 4,872.0 JPY.
What Stock Exchange Does Eisai Trade On?
Eisai is listed and trades on the Tokyo Stock Exchange.
What Is the Stock Symbol for Eisai?
The stock symbol for Eisai is "4523."
Does Eisai Pay Dividends? What’s The Current Dividend Yield?
The Eisai dividend yield is 3.21%.
What Is the Eisai Market Cap?
As of today, Eisai market cap is 1.38T JPY.
What Is Eisai's Earnings Per Share (TTM)?
The Eisai EPS (TTM) is 150.2.
When Is the Next Eisai Earnings Date?
Eisai will release its next earnings report on Nov 10, 2026.
From a Technical Analysis Perspective, Is 4523 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Eisai Stock Split?
Eisai has split 2 times.
How Many Employees Does Eisai Have?
Eisai has 10543 employees.
What is the current trading status of Eisai (4523)?
As of Aug 14, 2026, Eisai (4523) is trading at a price of 4,872.0 JPY, with a previous close of 4,872.0 JPY. The stock has fluctuated within a day range of 4,852.0 JPY to 4,902.0 JPY, while its 52-week range spans from 3,660.0 JPY to 5,349.0 JPY.
What Is Eisai (4523) Price Target According to Analysts?
The average 12-month price target for Eisai is 4,496.4 JPY, with a high estimate of 5500 JPY and a low estimate of 3200 JPY. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -7.71% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.